Ionis shares saw a big pop in pre market trading on Monday, rising 37% to $40.10 after being down 53% year to date. The big move came after news revealed that an experimental treatment for a rare children’s spine disorder that was developed by Ionis (Nusinersen), has achieved the primary endpoint of a late-stage clinical … Continue reading “Ionis Pharmaceuticals (IONS) Achieves Major Milestone”
